UTI AMC Q1 FY27: Profit up, board meet Oct 23

Why UTI AMC’s latest update matters

UTI Asset Management Company Ltd (UTI AMC) reported its Q1 FY27 results for the quarter ended June 30, 2026, and also flagged a key upcoming date for investors. The company said its Board of Directors will meet on October 23, 2026 to consider and approve the un-audited standalone and consolidated financial results for the quarter and half-year ended September 30, 2026. The combination of quarterly performance disclosures and the upcoming board meeting puts focus on operating trends, market-linked income, and asset growth.

While the quarter showed year-on-year improvement in profit metrics, the disclosures also highlight that parts of profitability were supported by fair value gains. At the same time, UTI AMC’s mutual fund AUM numbers point to continued retail participation, including growth in SIP-linked assets.

Board meeting on October 23 for Q2 and H1 FY27 results

UTI AMC announced that its board will convene on Friday, October 23, 2026. The agenda is to consider and approve un-audited standalone and consolidated financial results for the quarter and half-year ended September 30, 2026. The company also said the board will discuss other general business matters.

The disclosure is relevant because it establishes a clear timeline for the next results update. Investors typically track these dates to understand when fresh operating, AUM, and profitability data will be available.

Q1 FY27 results: multiple profit lines investors should separate

For Q1 FY27, the company’s filings and summaries include more than one profit figure, reflecting different reporting scopes and classifications. One set of quarterly numbers shows revenue from operations of ₹438.91 crore and net profit of ₹217.80 crore for Q1 FY27, with year-on-year changes of +0.1% and +0.8%, respectively, and sharp quarter-on-quarter improvement in profit.

Separately, the company’s consolidated disclosures include a reported consolidated net profit of about ₹294 crore for the quarter ended June 30, 2026, compared with ₹237 crore in the corresponding period of the previous year. This consolidated profit growth was linked to fair value changes.

In addition to reported profit, the company also shared “core” metrics, including consolidated core PAT of ₹129 crore for Q1 FY27, up 6% year-on-year, and consolidated core EBITDA of ₹178 crore, up 3% year-on-year.

Standalone performance: revenue steady, profit higher QoQ

On a standalone basis, UTI AMC reported revenue of ₹438.91 crore for Q1 FY27. Standalone expenditure was ₹151.79 crore, with a year-on-year change of -1.4% and a quarter-on-quarter decline of -43.3%.

Standalone net profit was ₹217.80 crore, up 0.8% year-on-year, and sharply higher quarter-on-quarter as per the provided comparison. The quarterly table also cited revenue of ₹438 crore and net profit of ₹218 crore for the quarter to June 2026, which is broadly consistent with the standalone headline numbers.

“Core” operating metrics: standalone and consolidated snapshots

UTI AMC also provided core operating metrics aimed at showing underlying performance. Standalone core revenue was ₹308 crore for Q1 FY27. Standalone core EBITDA was ₹171 crore, up 1% year-on-year. Standalone core PAT was ₹119 crore, also up 1% year-on-year.

On a consolidated basis, core revenue was ₹379 crore. Consolidated core EBITDA was ₹178 crore, and consolidated core PAT was ₹129 crore. The company also stated that consolidated PAT increased 6% year-on-year to ₹129 crore, and consolidated EBITDA grew 3% year-on-year to ₹178 crore.

Consolidated reported numbers: fair value gains boosted profit

Another Q1 FY27 summary reported revenue from operations of ₹583.51 crore, reflecting a quarter-on-quarter increase of 49.51% from ₹390.28 crore and year-on-year growth of 6.70%. In the same summary, operating profit was ₹382.57 crore, PBDT was ₹381.01 crore, and profit before tax was ₹367.94 crore.

Net profit in this summary was ₹293.86 crore, with a year-on-year increase of 15.76% and a sharp quarter-on-quarter turnaround from a loss reported for Q4 FY26 in the same dataset. The company also reported consolidated net profit of ₹294 crore for Q1 FY27 in another disclosure, driven by fair value gains of ₹187 crore, alongside revenue from operations of ₹584 crore and total expenses of ₹217 crore.

Mutual fund AUM: QAAUM and SIP AUM growth

AUM trends were another key part of the quarter’s narrative. UTI AMC reported Mutual Fund Quarterly Average AUM (QAAUM) of ₹3,92,691 crore. It also reported total group AUM of slightly over ₹20,00,000 crore.

SIP AUM rose 8.05% year-on-year to ₹45,595 crore, indicating continued systematic investment participation. The company also cited significant digital adoption as a supporting factor during the quarter.

Corporate actions and audit process noted in disclosures

UTI AMC said its Board approved the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026 at a meeting held on July 22, 2026. The approval followed a recommendation from the Audit Committee. The company said a limited review report from its statutory auditor, B S R & Co. LLP, was submitted.

UTI AMC also conducted its 23rd AGM on July 21, 2026, where shareholders approved the audited financial statements for FY26, declared a final dividend, and re-appointed key personnel, as per the provided update.

Key numbers at a glance

Dates investors will track next

Market impact and what to watch

The quarter’s disclosures show two drivers operating together: core profitability linked to asset management operations, and reported profitability influenced by fair value changes. For investors, separating “core” results like consolidated core PAT of ₹129 crore from the reported consolidated profit of around ₹294 crore is important because the latter was explicitly linked to fair value gains of ₹187 crore.

On the operating side, AUM data such as MF QAAUM of ₹3,92,691 crore and SIP AUM of ₹45,595 crore offers a direct read on client assets and retail participation. The next major checkpoint will be October 23, 2026, when the board considers Q2 and H1 FY27 financial results for the period ended September 30, 2026.